CAR-T细胞患者ICU收治、管理与结局的六年趋势
该多中心回顾性队列纳入2018年1月至2023年9月美国8个中心接受CAR-T细胞治疗并入住ICU的成人患者。2018至2023年共2238例接受CAR-T治疗,398例(17.8%)需ICU照护。ICU收治率从2018年38.5%(95%CI 31.6-45.8%)降至2023年16.4%(95%CI 13.5-19.7%,p<0.0001)。2023年较2018年ICU患者更老(中位65岁 vs 58岁,p=0.003)、合并症指数更高(4 vs 3,p=0.005)、≥3级毒性更多(90.1% vs 69.9%,p=0.004);细胞因子释放综合征或免疫效应细胞相关神经毒性综合征相关死亡仍低(5.5%)。
要点
- 2018至2023年2238例CAR-T患者中398例(17.8%)需ICU,ICU收治率由2018年38.5%降至2023年16.4%(p<0.0001)。
- ICU入住原因中细胞因子释放综合征或免疫效应细胞相关神经毒性综合征占87.9%,该原因相关死亡率5.5%。
- 2023年 vs 2018年ICU患者中位年龄65岁 vs 58岁(p=0.003),合并症指数4 vs 3(p=0.005),≥3级毒性90.1% vs 69.9%(p=0.004)。
- ICU入院时SOFA≥10与院内死亡相关(OR 4.69,95%CI 2.44-9.01,p<0.0001);非细胞因子释放/神经毒性原因入ICU亦相关(OR 3.74,95%CI 1.91-7.3,p=0.0001)。
- 年龄与院内死亡相关(OR 1.02,95%CI 1-1.04,p=0.046)。
适用人群与场景
- 美国8个中心2018年1月至2023年9月接受CAR-T细胞治疗并入住ICU的成人患者。
- ICU患者中66.1%为男性,89.2%患淋巴瘤,中位年龄64岁(IQR 53-71岁)。
处置流程与药物剂量
- 较轻重度毒性(≤2级)使用皮质类固醇的比例从40.6%升至73.8%(p=0.0001)。
- 阿那白滞素使用率从5.5%升至56%(p<0.0001)。
研究设计与关键结果
- 多中心回顾性队列,2018年1月至2023年9月美国8个中心,2238例接受CAR-T细胞治疗,398例(17.8%)需ICU。
- ICU收治率从2018年38.5%(95%CI 31.6-45.8%)降至2023年16.4%(95%CI 13.5-19.7%,p<0.0001)。
- 2023年 vs 2018年:ICU患者中位年龄65岁(IQR 55-73) vs 58岁(IQR 48-67),p=0.003;合并症指数4(IQR 4-6) vs 3(IQR 2-4),p=0.005;≥3级毒性90.1% vs 69.9%,p=0.004。
- 细胞因子释放综合征或免疫效应细胞相关神经毒性综合征占ICU入住原因的87.9%,相关死亡率5.5%。
- 院内死亡相关因素:年龄OR 1.02(95%CI 1-1.04,p=0.046);ICU入院时SOFA≥10 OR 4.69(95%CI 2.44-9.01,p<0.0001);非细胞因子释放/神经毒性原因入ICU OR 3.74(95%CI 1.91-7.3,p=0.0001)。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- CAR-T后ICU收治率下降,但ICU患者更老、合并症更多、毒性级别更高,ICU死亡率仍低。
- ICU入院时SOFA≥10、非细胞因子释放/神经毒性原因入ICU及年龄与院内死亡相关,可据此识别高危患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate evolving management, ICU admission, and outcomes for critically ill chimeric antigen receptor (CAR) T-cell patients over a 6-year period.
DESIGN: Multicenter retrospective cohort study from January 2018 to September 2023.
SETTING: Eight U.S. centers.
PATIENTS: Adult CAR T-cell patients requiring ICU admission.
INTERVENTIONS: None.
METHODS: Summary statistics included mean, sd , median, and interquartile range (IQR). Fisher exact test or chi-square test were used to evaluate association between year treated and other categorical variables. Cochran-Armitage test was performed to assess significance of trends across years. Multivariable logistic regression was performed to assess covariates associated with mortality.
MEASUREMENTS AND MAIN RESULTS: Demographics, toxicity management, ICU admission, support modalities, toxicity severity, and survival (ICU, hospital, and 3-mo) were compared year-to-year. From 2018 to 2023, 2238 patients received CAR T cells, with increasing number of patients treated yearly; 398 (17.8%) required ICU care. Of those admitted to the ICU, 66.1% were male, 89.2% had lymphoma, and median age was 64 years (53-71 yr). ICU admission rates declined from 38.5% (95% CI, 31.6-45.8%) in 2018 to 16.4% in 2023 (95% CI, 13.5-19.7%; p < 0.0001). Cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome was the reason for ICU admission in 87.9%. In 2023 vs. 2018, ICU patients were older (median, 65 yr [IQR, 55-73 yr] vs. 58 yr [48-67 yr]; p = 0.003) with higher comorbidity indices (4 [4-6] vs. 3 [2-4]; p = 0.005) and more severe toxicities (≥ grade 3: 90.1% vs. 69.9%; p = 0.004). Corticosteroid use for less severe toxicities (≤ grade 2 toxicity: 73.8% vs. 40.6%; p = 0.0001) and anakinra use (56% vs. 5.5%; p < 0.0001) increased throughout the years. Mortality from cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome remained low (5.5%). Age, Sequential Organ Failure Assessment greater than or equal to 10 at ICU admission, and ICU admission for noncytokine release/neurotoxicity syndrome reasons were associated with hospital mortality (odds ratios, 1.02 [95% CI, 1-1.04; p = 0.046], 4.69 [2.44-9.01; p < 0.0001], and 3.74 [1.91-7.3; p = 0.0001], respectively).
CONCLUSIONS: ICU admission rates after CAR T-cell treatment are declining. Although ICU patients are older with higher severity of illness and toxicity grades, ICU mortality after CAR T-cell therapy remains low.
参考来源
- Rajendram P, Stephens RS, Brown ART, et al. Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICU. Crit Care Med. 2025. PMID: 41467744. doi:10.1097/CCM.0000000000007000
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。